Woldaregay Erku Abegaz
Addis Ababa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Woldaregay Erku Abegaz.
Clinical & Experimental Allergy | 2014
Alemayehu Amberbir; Girmay Medhin; Woldaregay Erku Abegaz; Charlotte Hanlon; Karen Robinson; Andrew W. Fogarty; John Britton; Andrea Venn; Gail Davey
An inverse relation between Helicobacter pylori infection and allergic disease has been reported by a range of independent epidemiological studies, but evidence from longitudinal studies is scarce.
Journal of Medical Microbiology | 2014
Tsegahun Manyazewal; Zufan Sisay; Sibhatu Biadgilign; Woldaregay Erku Abegaz
Most HIV positive people have not been tested for viral hepatitis and their treatments have not been optimized for possible co-infections. The aim of this study was to investigate the serological pattern of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among antiretroviral (ARV)-naive and -experienced HIV co-infected adults in Addis Ababa, Ethiopia. A total of 500 frozen HIV positive serum and plasma samples collected from ARV-naive (n = 250) and -experienced (n = 250) adults were randomly selected and screened for HBsAg, anti-HBs, HBeAg and anti-HCV using rapid two-site sandwich immunochromatographic assay. The test was performed at Aklilu Lemma Institute of Pathobiology, Addis Ababa University. Positive specimens for HBsAg and anti-HCV markers were further confirmed using third generation ELISA. Of the 500 specimens tested, 15 (3 %), 58 (11.6 %), 3 (0.6 %), 18 (3.6 %), 3 (0.6 %) and 1 (0.2 %) were positive for HBsAg, anti-HBs, HBeAg, anti-HCV, HBsAg and HBeAg, and HBsAg and anti-HBs markers, respectively. No specimen tested positive for both HBeAg and anti-HBs, and 442 (88.4 %) individuals were non-immune to HBV. Of the 250 ARV-naive individuals, 8 (3.2 %), 33 (13.2 %), 2 (0.8 %), 10 (4 %), 2 (0.8 %), and 1 (0.4 %) were positive for HBsAg, anti-HBs, HBeAg, anti-HCV, HBsAg and HBeAg, and HBsAg and anti-HBs markers, respectively. Of the 250 ARV-experienced individuals, 7 (2.8 %), 25 (10 %), 1 (0.4 %), 8 (3.2 %), 1 (0.4 %), and 0 (0 %) were positive for HBsAg, Anti-HBs, HBeAg, anti-HCV, HBsAg and HBeAg, and HBsAg and anti-HBs markers, respectively. In summary, seroprevalence of HIV/HBV and HIV/HCV co-infections was lower in Addis Ababa, Ethiopia, than in Sub-Saharan Africa and globally. HBV and HCV infections were not significantly different between HIV positive subjects who were or who were not on ARV. This suggests that the two groups have equal chance of being infected with these two viruses; despite this, disease progression could be different.
Antiviral Therapy | 2008
Woldaregay Erku Abegaz; Zehava Grossman; Dawit Wolday; Daniela Ram; Jonathan E. Kaplan; Kassim Sibide; Tadesse Wuhib; Shabbir Ismael; John N. Nkengasong; Teferi Mekonen; Hiwot Berhanu; Tsehaynesh Messele; Sileshi Lulseged; Shlomo Maayan; Yohannes Mengistu
BMC Pediatrics | 2013
Silenat Biressaw; Woldaregay Erku Abegaz; Markos Abebe; Workeabeba Abebe Taye; Mulugeta Belay
BMC Pediatrics | 2014
Dereje Hailu; Woldaregay Erku Abegaz; Mulugeta Belay
Archives of Virology | 2016
Zufan Sisay; Appolinaire Djikeng; Nega Berhe; Gurja Belay; Wondwossen A. Gebreyes; Woldaregay Erku Abegaz; Moses N. Njahira; Qiuhong Wang; Linda J. Saif
BMC Hematology | 2015
Muluken Assefa; Woldaregay Erku Abegaz; Aster Shewamare; Girmay Medhin; Mulugeta Belay
Archives of Virology | 2016
Zufan Sisay; Appolinaire Djikeng; Nega Berhe; Gurja Belay; Woldaregay Erku Abegaz; Qiuhong Wang; Linda J. Saif
International Journal of Infectious Diseases | 2012
Tsegahun Manyazewal; Zufan Sisay; Woldaregay Erku Abegaz
International Journal of Infectious Diseases | 2014
J.B. Weyesa; Woldaregay Erku Abegaz; M.B. No